Novel strategies for prevention and treatment of influenza.
Influenza viruses continue to be a major health challenge due to antigenic variation in envelope proteins and animal reservoirs for the viruses. Of particular concern is an anticipated influenza pandemic in the near future. Vaccination is currently the most effective means of reducing morbidity and mortality during influenza epidemics. In addition, neuraminidase inhibitors have substantially improved antiviral therapy for influenza. However, influenza infection in children and the elderly remain problematic. Furthermore, major innovations in prevention and therapy will be needed to deal with an influenza pandemic. This review assesses available and investigational antivirals and vaccines for influenza, emphasising novel approaches that may improve ability to cope with infection in children and the elderly or during a pandemic. Some adverse sequelae of influenza appear to relate to impairment or pathogenic activation of immune responses. Exciting recent findings in this area, with relevance to influenza treatment, are reviewed.
Kandel
Ruth
R
Harvard University School of Medicine, Hebrew Rehabilitation Center for Aged Internal Medicine/Geriatrics, 1200 Centre Street, Boston, MA 02131-1097, USA.
Hartshorn
Kevan L
KL
D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology / Q000627:therapeutic use*; D004196:Disease Outbreaks / Q000517:prevention & control*; D015507:Drugs, Investigational / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D007252:Influenza Vaccines / Q000494:pharmacology / Q000627:therapeutic use*; D007251:Influenza, Human / Q000188:drug therapy* / Q000453:epidemiology / Q000517:prevention & control*; D009975:Orthomyxoviridae / Q000187:drug effects
D000998:Antiviral Agents; D015507:Drugs, Investigational; D007252:Influenza Vaccines